Systemic sclerosis & Raynaud's
Application of the Scleroderma Clinical Trials Consortium Damage Index in patients with juvenile systemic sclerosis
Authors' conclusion
There are differences in clinical presentations between adult SSc patients and jSSc patients. The SCTC-DI can be applied to JSSc patients
Study context
- Population
- Patients with Juvenile Systemic Sclerosis (jSSc) at Peking Union Medical College Hospital, January 2012 to January 2024
- Participants
- 64 patients
- Exposure
- Scleroderma Clinical Trials Consortium-Damage Index (SCTC-DI) vs J4S in jSSc; jSSc vs adult systemic sclerosis (SSc)
- jSScn = 64
- Outcome
- Application of SCTC-DI in jSSc
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Higher baseline SCTC-DI score associated with greater progression of organ damage
- P = 0.001
Observational data: associations, not effects.
Further findings
Organ involvement, jSSc vs adult SSc
- jSSc had a lower incidence of gastrointestinal and urinary system involvement than adult SSc
Original publication
Application of the Scleroderma Clinical Trials Consortium Damage Index in patients with juvenile systemic sclerosis. Pediatr Rheumatol Online J. Published 14 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →